In 2023, for the first time in five years, drug overdose deaths in the US saw a decrease.

It's as if someone has suddenly flipped a switch, and now you see the room exactly as it is," she remarked. "All those vapes and cigarettes you've indulged in over the years, they just don't hold the same allure anymore.It's incredibly strange. Very strange indeed."

This sentiment is echoed by thousands of individuals who are prescribed medications belonging to the GLP-1 receptor agonists class, estimated to be used by around 15 million Americans, according to recent polls. In response to this phenomenon, Novo Nordisk, the manufacturer of Ozempic, has announced its intention to investigate further.

The company aims to commence a clinical trial this month, evaluating the impact of semaglutide, the active component in Ozempic, and other medications on alcohol consumption.

Although reducing drinking is not the primary objective of the study, Novo Nordisk seeks to better understand the broader effects of their medications on patient behaviors and habits.